IBDEI0M6 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10519,2)
 ;;=^332789
 ;;^UTILITY(U,$J,358.3,10520,0)
 ;;=362.02^^44^566^16
 ;;^UTILITY(U,$J,358.3,10520,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10520,1,3,0)
 ;;=3^DM PDR
 ;;^UTILITY(U,$J,358.3,10520,1,4,0)
 ;;=4^362.02
 ;;^UTILITY(U,$J,358.3,10520,2)
 ;;=^268610
 ;;^UTILITY(U,$J,358.3,10521,0)
 ;;=367.9^^44^566^18
 ;;^UTILITY(U,$J,358.3,10521,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10521,1,3,0)
 ;;=3^Disorder of Refraction
 ;;^UTILITY(U,$J,358.3,10521,1,4,0)
 ;;=4^367.9
 ;;^UTILITY(U,$J,358.3,10521,2)
 ;;=^35634
 ;;^UTILITY(U,$J,358.3,10522,0)
 ;;=373.2^^44^566^36
 ;;^UTILITY(U,$J,358.3,10522,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10522,1,3,0)
 ;;=3^Meibomianitis
 ;;^UTILITY(U,$J,358.3,10522,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,10522,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,10523,0)
 ;;=V58.69^^44^566^34
 ;;^UTILITY(U,$J,358.3,10523,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10523,1,3,0)
 ;;=3^Long Term Use of Medication
 ;;^UTILITY(U,$J,358.3,10523,1,4,0)
 ;;=4^V58.69
 ;;^UTILITY(U,$J,358.3,10523,2)
 ;;=^303460
 ;;^UTILITY(U,$J,358.3,10524,0)
 ;;=379.24^^44^566^51
 ;;^UTILITY(U,$J,358.3,10524,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10524,1,3,0)
 ;;=3^Vitreous Floaters
 ;;^UTILITY(U,$J,358.3,10524,1,4,0)
 ;;=4^379.24
 ;;^UTILITY(U,$J,358.3,10524,2)
 ;;=^88242
 ;;^UTILITY(U,$J,358.3,10525,0)
 ;;=V80.2^^44^566^47
 ;;^UTILITY(U,$J,358.3,10525,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10525,1,3,0)
 ;;=3^Screening for Eye Condition
 ;;^UTILITY(U,$J,358.3,10525,1,4,0)
 ;;=4^V80.2
 ;;^UTILITY(U,$J,358.3,10525,2)
 ;;=^295685
 ;;^UTILITY(U,$J,358.3,10526,0)
 ;;=V70.5^^44^566^48
 ;;^UTILITY(U,$J,358.3,10526,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10526,1,3,0)
 ;;=3^Screening,Occupational
 ;;^UTILITY(U,$J,358.3,10526,1,4,0)
 ;;=4^V70.5
 ;;^UTILITY(U,$J,358.3,10526,2)
 ;;=^295595
 ;;^UTILITY(U,$J,358.3,10527,0)
 ;;=365.11^^44^566^27
 ;;^UTILITY(U,$J,358.3,10527,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10527,1,3,0)
 ;;=3^Glaucoma Primary Open Angle
 ;;^UTILITY(U,$J,358.3,10527,1,4,0)
 ;;=4^365.11
 ;;^UTILITY(U,$J,358.3,10527,2)
 ;;=^51203
 ;;^UTILITY(U,$J,358.3,10528,0)
 ;;=365.70^^44^566^29
 ;;^UTILITY(U,$J,358.3,10528,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10528,1,3,0)
 ;;=3^Glaucoma Stage NOS
 ;;^UTILITY(U,$J,358.3,10528,1,4,0)
 ;;=4^365.70
 ;;^UTILITY(U,$J,358.3,10528,2)
 ;;=^340609
 ;;^UTILITY(U,$J,358.3,10529,0)
 ;;=365.74^^44^566^23
 ;;^UTILITY(U,$J,358.3,10529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10529,1,3,0)
 ;;=3^Glaucoma Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,10529,1,4,0)
 ;;=4^365.74
 ;;^UTILITY(U,$J,358.3,10529,2)
 ;;=^340516
 ;;^UTILITY(U,$J,358.3,10530,0)
 ;;=V43.1^^44^566^33
 ;;^UTILITY(U,$J,358.3,10530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10530,1,3,0)
 ;;=3^Lens Replacement NEC
 ;;^UTILITY(U,$J,358.3,10530,1,4,0)
 ;;=4^V43.1
 ;;^UTILITY(U,$J,358.3,10530,2)
 ;;=^69114
 ;;^UTILITY(U,$J,358.3,10531,0)
 ;;=369.4^^44^567^10
 ;;^UTILITY(U,$J,358.3,10531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10531,1,3,0)
 ;;=3^Legally Blind,USA Def
 ;;^UTILITY(U,$J,358.3,10531,1,4,0)
 ;;=4^369.4
 ;;^UTILITY(U,$J,358.3,10531,2)
 ;;=^268887
 ;;^UTILITY(U,$J,358.3,10532,0)
 ;;=369.01^^44^567^25
 ;;^UTILITY(U,$J,358.3,10532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10532,1,3,0)
 ;;=3^Total Impairment,Both Eyes
 ;;^UTILITY(U,$J,358.3,10532,1,4,0)
 ;;=4^369.01
 ;;^UTILITY(U,$J,358.3,10532,2)
 ;;=^268861
 ;;^UTILITY(U,$J,358.3,10533,0)
 ;;=369.02^^44^567^15
 ;;^UTILITY(U,$J,358.3,10533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10533,1,3,0)
 ;;=3^One Eye Near Total/Oth Eye NOS
 ;;
 ;;$END ROU IBDEI0M6
